Brief: Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
18/06/2024 12:14
June 18 (Reuters) - Zentalis Pharmaceuticals Inc
ZNTL.O :
* ZENTALIS PHARMACEUTICALS PROVIDES UPDATE ON AZENOSERTIB
CLINICAL
DEVELOPMENT PROGRAM
* ZENTALIS PHARMACEUTICALS PROVIDES UPDATE ON AZENOSERTIB
CLINICAL
DEVELOPMENT PROGRAM
* ZENTALIS PHARMACEUTICALS INC: FDA HAS PLACED A PARTIAL
CLINICAL
HOLD ON ZN-C3-001, DENALI AND TETON MONOTHERAPY STUDIES OF
AZENOSERTIB
* ZENTALIS PHARMACEUTICALS INC: MONOTHERAPY DATA TO BE
PRESENTED
IN SECOND HALF OF 2024
* ZENTALIS PHARMACEUTICALS INC: FDA ACTION FOLLOWS TWO
RECENT
DEATHS DUE TO PRESUMED SEPSIS IN DENALI STUDY
Source text for Eikon: ID:nGNX37pJk3
Further company coverage: ZNTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer